Celecoxib for the treatment of atherosclerosis

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.
   PubMed Web of Science ®Google Scholar
• Roger VL. Epidemiology of myocardial infarction. Med Clin North Am. 2007;91(4):537–552. ix.
   PubMed Web of Science ®Google Scholar
• Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) study. Circulation. 2015;131(24):2104–2113.
   PubMed Web of Science ®Google Scholar
• van Diepen JA, Berbee JF, Havekes LM, et al. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis. 2013;228(2):306–315.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Stone NJ. Reducing residual risk in secondary prevention of cardiovascular disease. Circulation. 2012;125(16):1958–1960.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013;23(9):799–807.
   PubMed Web of Science ®Google Scholar
• Berman JP, Farkouh ME, Rosenson RS. Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs. 2013;18(2):193–205.
   PubMed Web of Science ®Google Scholar
• Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol. 2002;13(5):497–504.
   PubMed Web of Science ®Google Scholar
• Belton O, Fitzgerald DJ. Cyclooxygenase isoforms and atherosclerosis. Expert Rev Mol Med. 2003;5(9):1–18.
   PubMedGoogle Scholar
• FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433–442.
   PubMed Web of Science ®Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40(9):1347–1365.
   PubMed Web of Science ®Google Scholar
• Tacconelli S, Capone ML, Sciulli MG, et al. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin. 2002;18(8):503–511.
   PubMed Web of Science ®Google Scholar
• Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38(3):225–242.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005;33(11):1567–1575.
   PubMed Web of Science ®Google Scholar
• Wang SL, Huang J, Lai MD, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5(1):37–42.
   PubMedGoogle Scholar
• Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105(15):1816–1823.
   PubMed Web of Science ®Google Scholar
• Stemme V, Swedenborg J, Claesson H, et al. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur J Vasc Endovasc Surg. 2000;20(2):146–152.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Prontera C, Pini B, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104(8):921–927.
   PubMed Web of Science ®Google Scholar
• Zhao S-P, Deng P, Huang H-G, et al. Expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and its significance. Clin Chem. 2005;51(11):2170–2173.
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Smith B, Pedersen AK, et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984;310(17):1065–1068.
   PubMed Web of Science ®Google Scholar
• Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306(5703):1954–1957.
   PubMed Web of Science ®Google Scholar
• Alcindor D, Krolikowski JG, Pagel PS, et al. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology. 2004;100(3):547–554.
   PubMed Web of Science ®Google Scholar
• Lin CP, Lin FY, Huang PH, et al. Endothelial progenitor cell dysfunction in cardiovascular diseases: role of reactive oxygen species and inflammation. Biomed Res Int. 2013;2013:845037.
   PubMedGoogle Scholar
• d’Audigier C, Cochain C, Rossi E, et al. Thrombin receptor PAR-1 activation on endothelial progenitor cells enhances chemotaxis-associated genes expression and leukocyte recruitment by a COX-2-dependent mechanism. Angiogenesis. 2015;18(3):347–359.
   PubMed Web of Science ®Google Scholar
• Terzuoli E, Meini S, Cucchi P, et al. Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation. PLoS One. 2014;9(1):e84358.
   PubMed Web of Science ®Google Scholar
• Lou J, Povsic TJ, Allen JD, et al. The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties. Thromb Res. 2010;126(3):e175–9.
   PubMed Web of Science ®Google Scholar
• He T, Lu T, d’Uscio LV, et al. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res. 2008;103(1):80–88.
   PubMed Web of Science ®Google Scholar
• Li Q, Sun W, Wang X, et al. Skin-derived mesenchymal stem cells alleviate atherosclerosis via modulating macrophage function. Stem Cells Transl Med. 2015;4(11):1294–1301.
   PubMed Web of Science ®Google Scholar
• Jacob S, Laury-Kleintop L, Lanza-Jacoby S. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice. J Surg Res. 2008;146(1):135–142.
   PubMed Web of Science ®Google Scholar
• Raval M, Frank PG, Laury-Kleintop L, et al. Celecoxib combined with atorvastatin prevents progression of atherosclerosis. J Surg Res. 2010;163(2):e113–22 .
   PubMed Web of Science ®Google Scholar
• Steffel J, Hermann M, Greutert H, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation. 2005;111(13):1685–1689.
   PubMed Web of Science ®Google Scholar
• Lada-Moldovan L, Kaloustian S, Bah TM, et al. Chronic pretreatment with celecoxib reduces infarct size. J Cardiovasc Pharmacol. 2009;54(1):31–37.
   PubMed Web of Science ®Google Scholar
• Zhao M, He X, Zhao M, et al. Low-dose celecoxib improves coronary function after acute myocardial ischaemia in rabbits. Clin Exp Pharmacol Physiol. 2012;39(3):233–240.
   PubMed Web of Science ®Google Scholar
• Chu LM, Robich MP, Bianchi C, et al. Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia. Am J Physiol Heart Circ Physiol. 2012;302(2):H479–88.
   PubMed Web of Science ®Google Scholar
• Gitlin JM, Loftin CD. Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. Cardiovasc Res. 2009;81(2):400–407.
   PubMed Web of Science ®Google Scholar
• Bea F, Blessing E, Bennett BJ, et al. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res. 2003;60(1):198–204.
   PubMed Web of Science ®Google Scholar
• Olesen M, Kwong E, Meztli A, et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J. 2002;36(6):362–367.
   PubMed Web of Science ®Google Scholar
• Burleigh ME, Babaev VR, Yancey PG, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39(3):443–452.
   PubMed Web of Science ®Google Scholar
• Metzner J, Popp L, Marian C, et al. The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice. J Mol Med (Berl). 2007;85(6):623–633.
   PubMed Web of Science ®Google Scholar
• Steffel J, Akhmedov A, Fähndrich C, et al. Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun. 2006;349(2):597–603.
   PubMed Web of Science ®Google Scholar
• Rossoni G, Muscara MN, Cirino G, et al. Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol. 2002;135(6):1540–1546.
   PubMed Web of Science ®Google Scholar
• Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 2001;104(7):820–825.
   PubMed Web of Science ®Google Scholar
• Timmers L, Sluijter JP, Verlaan CW, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation. 2007;115(3):326–332.
   PubMed Web of Science ®Google Scholar
• Burleigh ME, Babaev VR, Patel MB, et al. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice. Biochem Pharmacol. 2005;70(3):334–342.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–1080.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114(10):1028–1035.
   PubMed Web of Science ®Google Scholar
• Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006;113(16):1950–1957.
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906–2913.
   PubMed Web of Science ®Google Scholar
• Brophy JM, Lévesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007;93(2):189–194.
   PubMed Web of Science ®Google Scholar
• Fosbøl EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–197.
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27(14):1657–1663.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Fosbøl EL, Olsen A-MS, et al. Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. Int J Cardiol. 2013;168(2):832–837.
   PubMed Web of Science ®Google Scholar
• Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885–895.
   PubMed Web of Science ®Google Scholar
• Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clinical Trials. 2006;1(7):e33.
   PubMedGoogle Scholar
• Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum. 2006;55(4):531–536.
   PubMed Web of Science ®Google Scholar
• Abraham NS, El-Serag HB, Hartman C, et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther. 2007;25(8):913–924.
   PubMed Web of Science ®Google Scholar
• Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med. 2007;120(1):98.e9–16.
   PubMedGoogle Scholar
• Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford). 2007;46(3):435–438.
   PubMed Web of Science ®Google Scholar
• Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155–163.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Castellsague J, Stang MR, et al. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18(11):1016–1025.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068–2073.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Stürmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006;54(5):1378–1389.
   PubMed Web of Science ®Google Scholar
• Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99(3):132–140.
   PubMed Web of Science ®Google Scholar
• Chen L-C, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2007;16(7):762–772.
   PubMed Web of Science ®Google Scholar
• De Vecchis R, Baldi C, Di Biase G, et al. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014;62(6):437–448.
   PubMed Web of Science ®Google Scholar
• Rimon G, Sidhu RS, Lauver DA, et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci U S A. 2010;107(1):28–33.
   PubMed Web of Science ®Google Scholar
• Lee W, Suh J-W, Yang H-M, et al. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J. 2010;40(7):321–327.
   PubMedGoogle Scholar
• Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 2):1509–1515.
   PubMed Web of Science ®Google Scholar
• Jermany J, Branson J, Schmouder R, et al. Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. J Clin Pharmacol. 2005;45(10):1172–1178.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364(9435):675–684.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–481.
   PubMed Web of Science ®Google Scholar
• Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. Bmj. 2005;330(7504):1370.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. Jama. 2006;296(13):1633–1644.
   PubMed Web of Science ®Google Scholar
• Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004;177(2):235–243.
   PubMed Web of Science ®Google Scholar
• Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007;357(4):360–369.
   PubMed Web of Science ®Google Scholar
• Burnier M. The safety of rofecoxib. Expert Opin Drug Saf. 2005;4(3):491–499.
   PubMedGoogle Scholar
• Atukorala I, Hunter DJ. Valdecoxib: the rise and fall of a COX-2 inhibitor. Expert Opin Pharmacother. 2013;14(8):1077–1086.
   PubMed Web of Science ®Google Scholar
• Huang W-F, Hsiao F-Y, Tsai Y-W, et al. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf. 2006;29(3):261–272.
   PubMed Web of Science ®Google Scholar
• Layton D, Hughes K, Harris S, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford). 2003;42(11):1354–1364.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Jakobsen AK, Askling J, et al. Safety of etoricoxib, celecoxib, and nonselective nonsteroidal antiinflammatory drugs in ankylosing spondylitis and other spondyloarthritis patients: a swedish national population-based cohort study. Arthritis Care Res (Hoboken). 2015;67(8):1137–1149.
   PubMed Web of Science ®Google Scholar
• Bäck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J. 2012;33(15):1928–1933.
   PubMed Web of Science ®Google Scholar
• White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002;89(4):425–430.
   PubMed Web of Science ®Google Scholar
• White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99(1):91–98.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Han P, Henry D. Cyclooxygenase-2 inhibitors and coronary occlusion–exploring dose-response relationships. Br J Clin Pharmacol. 2006;62(3):358–365.
   PubMed Web of Science ®Google Scholar
• Chenevard R, Hürlimann D, Béchir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107(3):405–409.
   PubMed Web of Science ®Google Scholar
• Flórez A, de Haro J, Martínez E, et al. Selective cyclooxygenase-2 inhibition reduces endothelial dysfunction and improves inflammatory status in patients with intermittent claudication. Rev Esp Cardiol. 2009;62(8):851–857.
   PubMed Web of Science ®Google Scholar
• Pelliccia F, Pasceri V, Granatelli A, et al. Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris. Am J Cardiol. 2006;98(11):1461–1463.
   PubMed Web of Science ®Google Scholar
• Koo B-K, Kim Y-S, Park K-W, et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet. 2007;370(9587):567–574.
   PubMed Web of Science ®Google Scholar
• Chung J-W, Yang H-M, Park K-W, et al. Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial. Circ Cardiovasc Interv. 2010;3(3):243–248.
   PubMed Web of Science ®Google Scholar
• Kang H-J, Oh I-Y, Chung J-W, et al. Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina. Eur Heart J. 2012;33(21):2653–2661.
   PubMed Web of Science ®Google Scholar
• Kim WH, Ko Y-G, Kang KW, et al. Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents. Yonsei Med J. 2012;53(1):68–75.
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Celecoxib to prevent restenosis–results from the COREA-TAXUS trial. Expert Opin Pharmacother. 2008;9(2):339–341.
   PubMed Web of Science ®Google Scholar
• Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157(4):606–612.
   PubMed Web of Science ®Google Scholar
• Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the nonsteroidal anti-inflammatory drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation. 2002;106(2):191–195.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Pride YB, Aylward PE, et al. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. J Thromb Thrombolysis. 2009;27(1):11–17.
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Bani D, Cinci L, et al. Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy. J Cell Mol Med. 2009;13(8b):2704–2712.
   PubMed Web of Science ®Google Scholar
• Feng G-S, Ma J-L, Wong BCY, et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World J Gastroenterol. 2008;14(28):4535–4539.
   PubMed Web of Science ®Google Scholar
• Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000;7(3):159–175.
   PubMedGoogle Scholar
• Krum H, Aw T-J, Liew D, et al. Blood pressure effects of COX-2 inhibitors. J Cardiovasc Pharmacol. 2006;47 Suppl 1(Suppl 1):S43–8.
   PubMed Web of Science ®Google Scholar
• Frolov RV, Ignatova II, Singh S. Inhibition of HERG potassium channels by celecoxib and its mechanism. PLoS One. 2011;6(10):e26344.
   PubMed Web of Science ®Google Scholar
• Pizzuto K, Averns HL, Baranchuk A, et al. Celecoxib-induced change in atrial electrophysiologic substrate in arthritis patients. Ann Noninvasive Electrocardiol. 2014;19(1):50–56.
   PubMed Web of Science ®Google Scholar